5 top performing pharma stock in last year: Wockhardt, Suven Life Sciences, Blue Jet Healthcare, Indraprastha Medical Corp and Strides Pharma Science make the cut

pharma

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Wockhardt, Suven Life Sciences, Blue Jet Healthcare, Indraprastha Medical Corp and Strides Pharma Science have emerged as top-performing stocks in one year ending June 30. The inclusion of Wockhardt and Suven Life Sciencies points to Indian investors taking bets on innovation.

Along with innovation the other themes that played out was turnaround stories, debt reduction, revitalisation and value unlocking - Strides Pharma fall in this category. The investors also handsomely rewarded good financial and operational performance in the form of the Indraprastha and young kid on the block Blue Jet Healthcare.

Here is list of top 5 top performing pharma and healthcare companies in last one year and why did they do well —

Wockhardt:
Wockhardt's impressive 149.42% return can be attributed to a strategic shift from a generics-focused company to a research-driven pharmaceutical leader. This transformation has been bolstered by significant debt reduction and advancements in its drug development pipeline, particularly with its novel antibiotics targeting superbugs. Key drivers include the approval and launch of Miqnaf in India and the impending US filing for Zaynich, both with QIDP status from the USFDA. The company's focus on regulatory readiness and plans to double production capacity have also instilled investor confidence, positioning Wockhardt to capitalize on emerging market opportunities and drive future growth.

Suven Life Sciences:
With a return of 130.18%, Suven Life Sciences' strong stock performance, despite its unprofitability and reliance on promoter funding, is a classic high-risk, high-reward scenario. Investors are betting on the immense potential of its Central Nervous System (CNS) drug pipeline, where a single successful "blockbuster" drug could lead to massive returns. This speculative optimism, primarily from retail investors, has created a powerful momentum effect, driving the price up. While the company's long-term potential is the main attraction, the investment carries significant risk.

Blue Jet Healthcare:
Blue Jet Healthcare's 116.28% return is underpinned by its exceptional financial performance and high management efficiency. The company despite facing a setback with massive explosion at its Mahad manufacturing unit days after its initial public offering, has demonstrated impressive annual revenue growth of 45.35%, outperforming its three-year compound annual growth rate (CAGR). With a high return on equity (ROE) of 26.94% and outstanding results in recent quarters, including significant net profit growth, the company has garnered positive ratings from analysts. This strong financial health and efficient management have been key drivers of its stock performance.

Indraprastha Medical Corp :
Indraprastha Medical Corp's 106.96% return reflects its consistent financial performance and healthy long-term growth outlook. The company has shown steady profit growth and a high return on equity, making it an attractive investment. Analysts have noted that the stock is undervalued based on its current and future earnings estimates, suggesting potential for further upside. The company's low debt-to-equity ratio and consistent dividend payments have also contributed to its positive market perception.

Strides Pharma Science:
Strides Pharma Science has delivered a strong return of 104.88%, driven by a combination of debt reduction, impressive profit growth, and strategic corporate actions. The company has successfully reduced its debt and delivered a good profit growth of 34.3% CAGR over the last five years. Key strategic moves, such as the demerger and planned listing of its subsidiary, OneSource, have been received positively by the market. Furthermore, receiving tentative approval from the USFDA for an HIV treatment drug has also been a significant catalyst for the stock's performance.